SAM
AXSM icon

Smartleaf Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Smartleaf Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.2K Hold
316
– – ﹤0.01% 1296
2026
Q1 		$50.7K Sell
316
-58
-16% -$10K ﹤0.01% 1443
2025
Q4 		$55.6K Buy
374
+175
+88% +$24.4K ﹤0.01% 1493
2025
Q3 		$23.4K Buy
199
+84
+73% +$9.46K ﹤0.01% 1747
2025
Q2 		$11.9K Sell
115
-74
-39% -$7.84K ﹤0.01% 1767
2025
Q1 		$22.4K Buy
189
+7
+4% +$797 ﹤0.01% 1555
2024
Q4 		$15.4K Buy
182
+105
+136% +$9.66K ﹤0.01% 1792
2024
Q3 		$6.9K Buy
77
+22
+40% +$1.92K ﹤0.01% 1973
2024
Q2 		$4.4K Buy
+55
New +$4.07K ﹤0.01% 1861

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Smartleaf Asset Management's AXSM Position: Q2 2026 in Review

Smartleaf Asset Management held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 316 shares worth $76.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1296.

Smartleaf Asset Management first reported a position in AXSM in Q2 2024 and has held it in 9 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Smartleaf Asset Management held 316 shares of Axsome Therapeutics worth $76.2K as of Q2 2026.
  • Smartleaf Asset Management left its Axsome Therapeutics share count unchanged in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1296 holding.
  • Smartleaf Asset Management first reported a position in Axsome Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.